[Skip to Content]
[Skip to Content Landing]
Views 1,030
Citations 0
Comment & Response
January 22/29, 2014

Hormone Therapy Use and Outcomes in the Women’s Health Initiative Trials—Reply

Author Affiliations
  • 1Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
  • 2Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California
  • 3Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington
JAMA. 2014;311(4):417-418. doi:10.1001/jama.2013.285163

In Reply Dr Roehm requests more information about the gallbladder disease outcome in the WHI trials. The goal of our article was to provide a comprehensive, integrated overview of findings from the 2 hormone therapy trials, including results from extended postintervention follow-up.

Due to the large number of outcomes presented (including primary and secondary adjudicated end points and quality-of-life outcomes), we only had space to present age-stratified analyses for the primary and secondary outcomes. We presented the hazard ratio (HR) for gallbladder disease in the overall cohort for each trial and noted that no significant differences by age group were observed.

First Page Preview View Large
First page PDF preview
First page PDF preview